N-[3-chloro-5-(trifluoromethoxy)benzyl]-N-(tetrahydro-2H-pyran-4-yl)-1H-1,2,4-triazole-3-carboxamide | 1245711-44-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-[3-chloro-5-(trifluoromethoxy)benzyl]-N-(tetrahydro-2H-pyran-4-yl)-1H-1,2,4-triazole-3-carboxamide
• 英文别名: N-[[3-chloro-5-(trifluoromethoxy)phenyl]methyl]-N-(oxan-4-yl)-1H-1,2,4-triazole-5-carboxamide
• CAS: 1245711-44-7
• 化学式: C₁₆H₁₆ClF₃N₄O₃
• 分子量: 404.776
• InChiKey: OCLHZNIONRDUND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  80.3
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• GLYCINE TRANSPORTER INHIBITING SUBSTANCES
  申请人：Yasuhara Akito

  公开号：US20120010414A1

  公开（公告）日：2012-01-12

  The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, and sleep disorder:

  本发明旨在提供基于甘氨酸摄取抑制作用的新型化合物，其化学式为[I]或其药学上可接受的盐，可用于预防或治疗精神分裂症、阿尔茨海默病、认知功能障碍、痴呆、焦虑障碍（广泛性焦虑障碍、恐慌障碍、强迫性障碍、社交焦虑障碍、创伤后应激障碍、特定恐惧症、急性应激障碍等）、抑郁症、药物成瘾、痉挛、震颤和睡眠障碍等疾病的治疗。
• GLYCINE TRANSPORTER INHIBITOR
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：EP2409976A1

  公开（公告）日：2012-01-25

  The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, and sleep disorder:

  本发明旨在提供基于甘氨酸摄取抑制作用的新型式[I]化合物或其药学上可接受的盐，这些化合物可用于预防或治疗精神分裂症、阿尔茨海默病、认知功能障碍、痴呆症、焦虑症（广泛性焦虑症、恐慌症、强迫症、社交焦虑症、创伤后应激障碍、特殊恐惧症、急性应激障碍等）等疾病。抑郁症、药物成瘾、痉挛、震颤和睡眠障碍）：
• US8623898B2
  申请人：——

  公开号：US8623898B2

  公开（公告）日：2014-01-07